Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 5/20 | 0.64 |
| ▸ | SYK | P43405 | 1/20 | 0.61 |
| ▸ | WEE1 | P30291 | 1/20 | 0.58 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | BRD4 | O60885 | 3/20 | 0.54 |
| ▸ | IGF1R | P08069 | 3/20 | 0.54 |
| ▸ | STAT6 | P42226 | 1/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | ULK1 | O75385 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19203865 | 0.85 | CCNK (0.67) | SYKALKEGFRBRD4IGF1R | |
| SCHEMBL11916385 | 0.84 | FGFR1 (0.63) | FGFR1SYKWEE1ALKJAK2 | |
| SCHEMBL11915907 | 0.84 | FGFR1 (0.63) | FGFR1SYKWEE1ALKJAK2 | |
| SCHEMBL29989713 | 0.79 | JAK2 (0.61) | FGFR1SYKJAK2BRD4IGF1R | |
| SCHEMBL27087812 | 0.79 | JAK2 (0.61) | FGFR1SYKJAK2BRD4IGF1R | |
| SCHEMBL27403061 | 0.79 | ULK1 (0.61) | FGFR1SYKJAK2FLT3ULK1 | |
| SCHEMBL29989833 | 0.79 | STAT6 (0.55) | FGFR1SYKWEE1ALKJAK2 | |
| SCHEMBL27087838 | 0.79 | STAT6 (0.55) | FGFR1SYKWEE1ALKJAK2 | |
| SCHEMBL27403055 | 0.78 | SYK (0.53) | FGFR1SYKJAK2IGF1RSTAT6 | |
| SCHEMBL30135476 | 0.78 | JAK3 (0.65) | FGFR1SYKJAK2IGF1RSTAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | FGFR1 383/4885SYK 558/4885WEE1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.